Related Experiment Video

Updated: May 16, 2026

Cardiac Response to β-Adrenergic Stimulation Determined by Pressure-Volume Loop Analysis
08:05

Cardiac Response to β-Adrenergic Stimulation Determined by Pressure-Volume Loop Analysis

Published on: May 19, 2021

Pathophysiological relevance of the cardiac β2-adrenergic receptor and its potential as a therapeutic target to

Joaquín Pérez-Schindler1, Andrew Philp, Jesús Hernandez-Cascales

  • 1Biozentrum, University of Basel, Klingelbergstrasse 50/70, Basel 4056, Switzerland.

European Journal of Pharmacology
|November 28, 2012
PubMed

Insights

Beta-2 adrenoceptors (β(2)-AR) significantly influence heart function, impacting contractility and metabolism. Understanding β(2)-AR mechanisms is crucial for developing targeted therapies for heart conditions.

Area of Science:

  • Cardiology
  • Molecular Pharmacology
  • G protein-coupled receptors

Background:

  • Beta-adrenoceptors (β-ARs) regulate myocardial function, influencing cardiac performance, arrhythmias, and apoptosis.
  • While not the predominant subtype, β(2)-adrenoceptors contribute significantly to cardiac adrenergic effects.
  • Inhibition of β-ARs offers protection in heart failure with sympathetic over-stimulation.

Purpose of the Study:

  • To review the current understanding of β(2)-adrenoceptor roles in cardiac contractility, metabolism, cardiomyocyte survival, and arrhythmias.
  • To discuss therapeutic strategies involving β(2)-adrenoceptor stimulation for cardiovascular benefits.

Main Methods:

  • Literature review of existing research on β(2)-adrenoceptors in the heart.
  • Synthesis of findings on β(2)-AR signaling pathways and their functional consequences.
  • Analysis of therapeutic implications based on current knowledge.

Main Results:

  • β(2)-AR activation influences cardiac contractility, metabolism, and cardiomyocyte survival.
  • The precise mechanisms of β(2)-AR involvement in cardiac function require further elucidation.
  • Therapeutic stimulation may enhance contractility with reduced arrhythmogenic risk and protect against apoptosis.

Conclusions:

  • β(2)-adrenoceptors play a multifaceted role in cardiac physiology and pathophysiology.
  • Targeting β(2)-ARs presents potential therapeutic avenues for managing heart failure and other cardiovascular diseases.
  • Further research is needed to fully harness the protective and functional benefits of β(2)-AR modulation.

More Related Videos

Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System02:47

Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: